依普利酮的用法和用量

Eplerenone is a new generation of selective aldosterone antagonist used for essential hypertension and heart failure after myocardial infarction. For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

Eplerenone is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors but not on androgen and progesterone receptors. Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril.

What is the usage and dosage of eplerenone?

Usage and dosage:

1. Congestive heart failure after acute myocardial infarction: The recommended dose is 50 mg/time, once/day. The initial dose should be 25 mg/time, once/day, and within 4 weeks, the dose should be gradually increased to 50 mg/time, once/day as tolerated by the patient within 4 weeks.

2. Anti-hypertensive: Eplerenone can be used alone or in combination with other anti-hypertensive drugs. The recommended initial dose for use alone is 50mg/time, once/day. Obvious pressure-reducing effect will appear within four weeks of taking the medicine. If the pressure effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia.

Eplerenone should not be combined with potassium supplements, potassium-containing salts, or contraindicated drugs (potassium-sparing diuretics, strong inhibitors of CYP450 liver enzymes). Eplerenone non-steroidal anti-inflammatory drugs and lithium can affect the blood concentration of this product and affect its efficacy. Patients with high serum potassium, type 2 diabetes patients with microalbuminuria, patients with high serum creatinine levels, and patients with muscle anesthesia clearance <50 mL/min should not take eplerenone.